


## Treatment pathway for focal hyperhidrosis in Primary Care



**\*First-line: Oxybutynin 2.5mg IR (unlicensed indication):** start with 2.5mg OD and gradually titrate according to response to a maximum of 5mg QDS. Modified release (MR) tablets for use when immediate release oxybutynin not tolerated (dose as in BNF). Alternative options such as Tolterodine IR or Darifenacin could be offered if oxybutynin effective but not well tolerated (unlicensed indications).

Propantheline bromide is licenced for hyperhidrosis, start with 15mg OD and gradually titrate according to response (see SPC for more details). However it is more expensive option than above, only use if first line options are not tolerated.

Glycopyrronium bromide. Not recommended for prescribing in Primary or Secondary Care. (MOPB 2017) Review patients on glycopyrronium bromide if suitable for switching to oxybutynin.

Please refer also to WECCG website for [“Anticholinergic side effects and Prescribing Guidance”](#).